기본 정보
- CAS
1722-62-9- 표준 SMILES
Cc1cccc(C)c1NC(=O)C1CCCCN1C.Cl- InChIKey
RETIMRUQNCDCQB-UHFFFAOYSA-N- 분자식
- C15H23ClN2O
- 평균 분자량
- 282.81 g/mol
- 단동위원소 질량
- 282.14989104
개요
Mepivacaine hydrochloride is the hydrochloride salt of mepivacaine. It is used as a local anaesthetic. It has a role as a local anaesthetic. It is a hydrochloride and a piperidinecarboxamide. It is functionally related to a mepivacaine.
이름 및 식별자
- 우선 이름
- Mepivacaine Hydrochloride
- IUPAC
- N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide;hydrochloride
- 현지명
- 메피바카인염산염
- 영어명
- Mepivacaine hydrochloride
- 분자식
- C15H22N2O.ClH
- 분자량
- 282.81
이름 및 동의어
Mepivacaine hydrochloride1722-62-9Mepivacaine HCLScandicainOptocainScandonest PlainPolocaine-MpfArestocaine hydrochlorideMepivacaine MonohydrochlorideISOCAINE HYDROCHLORIDE1-Methyl-2',6'-pipecoloxylidide hydrochloride1-Methyl-2',6'-pipecoloxylidide monohydrochloride
이름 더 보기
메피바카인염산염N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide hydrochlorideMepivacaine ImpurityMeaverinMepidentMepicatonChlorocainCarbocainaScandonest
4VFX2L7EM5NSC-758674(1-Methyl-DL-piperidine-2-carboxylic acid)-2,6-dimethylanilide hydrochlorideCHEBI:67602-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, hydrochloride (1:1)N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide hydrochloride (1:1)Iq Dental MepivacaineScandonest 3% Plain
데이터베이스 식별자
- CAS
1722-62-9
물성
구조 계산 물성
- 극성 표면적
- 32.3 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 2
- 회전 가능 결합 수
- 2
- 무거운 원자 수
- 19
- 형식 전하
- 0
- 복잡도
- 282
실험 및 물리화학적 성질
Solubility>42.4 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
Breast Feeding; Lactation; Anesthetics, Local
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal Drugs
Active Ingredients (Mepivacaine Hydrochloride) -> FDA Greenbook
Pharmaceuticals -> UK Veterinary Medicines Directorate List
Collision Cross Section157.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
물리화학적 성질
- 녹는점
- 255 · 255-257°C (dec.)
- 저장 조건
- 2 · 2-8°C
- 용해도
- 2 O: · H2O: 용해성20mg/mL, 투명
- 물리적 상태
- 가루
- 색상
- 흰색에서 베이지색
- 수용성
- 2 O: · H2O: 20mg/mL, clear
- InChI
- InChI=1S/C15H22N2O.ClH/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3;/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18);1H
- InChIKey
- RETIMRUQNCDCQB-UHFFFAOYSA-N
- SMILES
- C1(=C(C)C=CC=C1C)NC(=O)C1CCCCN1C.Cl
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
Danger
H301 (66.1%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P273, P301+P316, P301+P317, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 62 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
유해성 정보
Regulatory InformationMepivacaine hydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (66.1%)
독성 정보
Treatment
Treatment of a patient with toxic manifestations consists of assuring and maintaining a patient airway and supporting ventilation (respiration) as required. This usually will be sufficient in the management of most reactions. Should a convulsion persist despite ventilatory therapy, small increments of anticonvulsive agents may be given intravenously, such as benzodiazephine (e.g., diazepam) or ultrashort-acting barbiturates (e.g., thiopental or thiamylal) or short-acting barbiturates (e.g., pentobarbital or secobarbital). Cardiovascular depression may require circulatory assistance with intravenous fluids and/or vasopressor (e.g., Ephedrine) as dictated by the clinical situation. (L1712)
Exposure Routes
화학 및 산업
약리 정보
Metabolism/Metabolites
Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites. Route of Elimination: It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites. Half Life: The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
FDA Pharmacological Classification
MEPIVACAINE HYDROCHLORIDE
Amides [CS]; Amide Local Anesthetic [EPC]; Local Anesthesia [PE]
POLOCAINE (MEPIVACAINE HCL)
Amide Local Anesthetic [EPC]; Amides [CS]; Local Anesthesia [PE]
MeSH Pharmacological Classification
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.
용도 및 제조
UsesFor production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
General Manufacturing Information
관련 반응
2건
화합물 노트
불러오는 중…